BAILLIE GIFFORD & CO 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-05 10:24 am Sale |
2024-06-28 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
BAILLIE GIFFORD & CO | 6,032,656 4.770% |
-934,441 (-13.41%) |
Filing |
| 2024-01-29 12:18 pm Sale |
2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
BAILLIE GIFFORD & CO | 6,967,097 5.550% |
-2,440,774 (-25.94%) |
Filing |
| 2023-01-19 12:08 pm Sale |
2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
BAILLIE GIFFORD & CO | 9,407,871 7.650% |
-1,208,880 (-11.39%) |
Filing |
| 2022-01-18 07:06 am Purchase |
2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
BAILLIE GIFFORD & CO | 10,616,751 8.880% |
1,484,329 (+16.25%) |
Filing |
| 2021-02-01 10:12 am Purchase |
2020-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
BAILLIE GIFFORD & CO | 9,132,422 7.860% |
945,699 (+11.55%) |
Filing |